Showing results (371-380 of 406) with videos related to

Sort By:
Pageof 41
Cancer Research|January 1, 1990
Immunomodulatory properties and toxicity of interleukin 2 in patients with cancerW J Urba, R G Steis, D L Longo, et al.
Clinical Immunology (Orlando, Fla.)|March 18, 1999
Conditioned immune response to interferon-gamma in humansD L Longo, P L Duffey, W C Kopp, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|June 1, 1984
Kaposi's sarcoma of the head and neck in the acquired immune deficiency syndromeC A Patow, R Steis, D L Longo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1988
The determination of an immunologically active dose of interferon-gamma in patients with melanomaA E Maluish, W J Urba, D L Longo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1991
Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancerL H Pai, M A Bookman, R F Ozols, et al.
Journal of the National Cancer Institute|June 3, 1992
Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changesJ B Ochoa, B Curti, A B Peitzman, et al.
Cancer Research|September 1, 1985
Interleukin 2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemiaT A Waldmann, D L Longo, W J Leonard, et al.
Blood|October 1, 1991
Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2aJ W Smith, D L Longo, W J Urba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 1991
Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPPD L Longo, P L Duffey, V T DeVita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 1991
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trialD L Longo, V T DeVita, P L Duffey, et al.
Pageof 41